Drugs / PRA052
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05603182 | Nov 2022 → Feb 2024 | — | Prometheus Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRA052 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05603182 ↗ |
| Route | Intravenous | “Subjects will receive a single intravenous or subcutaneous dose of PRA052 in a dose escalation format” NCT05603182 ↗ |
| Route | Subcutaneous | “Subjects will receive a single intravenous or subcutaneous dose of PRA052 in a dose escalation format” NCT05603182 ↗ |